ACADIA Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary

• ACADIA Pharmaceuticals Inc ACAD.OQ reported quarterly adjusted earnings of 16 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of 20 cents. The mean expectation of twenty analysts for the quarter was for earnings of 14 cents per share. Wall Street expected results to range from 4 cents to 22 cents per share.

• Revenue rose 9.3% to $264.57 million from a year ago; analysts expected $261.81 million.

• ACADIA Pharmaceuticals Inc's reported EPS for the quarter was 16 cents​.

• The company reported quarterly net income of $26.67 million.

• ACADIA Pharmaceuticals Inc shares had risen by 9.6% this quarter and gained 28.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 12.5% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy," 6 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for ACADIA Pharmaceuticals Inc is $30.50, about 22.5% above its last closing price of $23.64

This summary was machine generated from LSEG data August 6 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)